Clinical Trial Update: RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 study of RMC-5552 as monotherapy in adults with recurrent glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• RMC-5552

Snippet

Sponsor: Nicholas Butowski | Conditions: Glioblastoma, Recurrent Glioblastoma | Phase 1 | Status: TERMINATED